Agilvax, Inc., an Albuquerque-based start-up company developing several vaccines for infectious diseases and cancer immunotherapies, has announced that Faith L. Charles, partner in Thompson Hine‘s Corporate Transactions & Securities practice group and chair of the firm’s Life Sciences group, has been elected to Agilvax’s board of directors. Agilvax uses a proprietary virus-like-particle (VLP) platform technology developed at the University of New Mexico by UNM Dr. David Peabody and Dr. Bryce Chackerian from the Department of Molecular Genetics & Microbiology. The VLP technology is used to rapidly identify and develop ideal vaccine candidates that are safe and can be manufactured rapidly at low cost. To read more about Faith Charles, see the Agilvax press release, reprinted below.
FAITH CHARLES JOINS AGILVAX’S BOARD OF DIRECTORS
Albuquerque, NM- September 14, 2016- Agilvax, Inc. today announced that Faith L. Charles, partner in Thompson Hine‘s Corporate Transactions & Securities practice group and chair of the firm’s Life Sciences group, has been elected to Agilvax’s board of directors, effective September 13, 2016.
Mrs. Charles has 25 years of experience as a corporate and securities lawyer representing public and private life science companies at all stages of development. She is known in the industry as an astute business advisor who brings guidance on growth strategies as well as legal expertise.
“I am excited and pleased that Faith is joining Agilvax’s board. Her wealth of experience advising startup and developmental stage life science companies will provide invaluable guidance to Agilvax as the company continues to grow and achieve technical milestones,” said Federica Pericle, Agilvax’s President & CEO.
“I admire Agilvax for its innovative approach in treating and preventing disease, and I am honored to be joining such a dynamic leadership team,” said Mrs. Charles. “I have tremendous respect for Federica and the other accomplished board members, and I look forward to working with them.”
Mrs. Charles has authored several articles and presentations on topics including alternative financing strategies, strategic collaborations, and biotech entrepreneurs. She has been featured in Crain’s New York and profiled in The New York Times. She has earned recognition as a BTI Client Service All-Star for service excellence, and from LMG Life Sciences for her transactional and Life Sciences expertise. She is the founder and co-chair of the New York Metro Chapter of Women in Bio and was recently selected as one of 20 executives for Women in Bio’s first Boardroom Ready Program.
Mrs. Charles’ specialties include U.S. and global business transactions and technology transfers; angel and venture capital financings; private placements; public offerings (equity and debt); mergers and acquisitions; spin-offs, joint ventures, licensing and other strategic collaborations; alternative financings; corporate governance; and compliance with SEC, NYSE, MKT, NASDAQ and securities regulatory issues. Mrs. Charles holds a Bachelor’s degree from Barnard College and earned her J.D. from the George Washington University.
About Agilvax
Agilvax (www.agilvax.com) is a biotechnology company that is developing targeted vaccines and cancer stem cell immunotherapies based on a proprietary virus-like particle (VLP) platform technology. The technology integrates epitope identification and immunogenic presentation in a single platform. The Company was founded in 2011 and has headquarters in Albuquerque, NM and offices in El Paso, TX.